Theranexus Société Anonyme announced that it has issues 1,930,009 common shares at a price of â¬1.28 million for the gross proceeds of â¬2.470412 million on July 12, 2023. The transactions included participation from Beyond Batten Disease Foundation and individual investors.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
1.12 EUR | +0.45% | +1.82% | 0.00% |
Apr. 29 | Theranexus Société Anonyme Reports Earnings Results for the Full Year Ended December 31, 2023 | CI |
Apr. 19 | Theranexus: share price rises following promising trial results | CF |
Annual profits - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
0.00% | 9.36M | |
+3.91% | 109B | |
+10.87% | 105B | |
+1.28% | 22.25B | |
-13.14% | 22.09B | |
-7.05% | 18.68B | |
-38.36% | 17.58B | |
-10.66% | 16.85B | |
+3.75% | 13.76B | |
+36.70% | 12.46B |
- Stock Market
- Equities
- ALTHX Stock
- News Theranexus
- Theranexus Société Anonyme announced that it has received €2.470412 million in funding